{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:44:22Z","timestamp":1787816662587,"version":"build-2784847793"},"publisher-location":"New York, NY","reference-count":29,"publisher":"Springer US","isbn-type":[{"value":"9781071641590","type":"print"},{"value":"9781071641606","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4160-6_20","type":"book-chapter","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T11:22:48Z","timestamp":1733138568000},"page":"297-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Generating MVA-Vector Vaccine Candidates and Testing Them in Animal Models"],"prefix":"10.1007","author":[{"given":"Alina","family":"Tscherne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meyer zu Natrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Kalodimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asisa","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"20_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","volume":"97","author":"A Volz","year":"2017","unstructured":"Volz A, Sutter G (2017) Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res 97:187\u2013243. https:\/\/doi.org\/10.1016\/bs.aivir.2016.07.001","journal-title":"Adv Virus Res"},{"issue":"5990","key":"20_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/312163a0","volume":"312","author":"MP Kieny","year":"1984","unstructured":"Kieny MP, Lathe R, Drillien R et al (1984) Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 312(5990):163\u2013166. https:\/\/doi.org\/10.1038\/312163a0","journal-title":"Nature"},{"issue":"3","key":"20_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1017\/s0950268800052535","volume":"116","author":"PP Pastoret","year":"1996","unstructured":"Pastoret PP, Brochier B (1996) The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiol Infect 116(3):235\u2013240. https:\/\/doi.org\/10.1017\/s0950268800052535","journal-title":"Epidemiol Infect"},{"issue":"22","key":"20_CR4","doi-asserted-by":"publisher","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","volume":"89","author":"G Sutter","year":"1992","unstructured":"Sutter G, Moss B (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89(22):10847\u201310851. https:\/\/doi.org\/10.1073\/pnas.89.22.10847","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 5","key":"20_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","volume":"72","author":"H Meyer","year":"1991","unstructured":"Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72(Pt 5):1031\u20131038. https:\/\/doi.org\/10.1099\/0022-1317-72-5-1031","journal-title":"J Gen Virol"},{"issue":"11","key":"20_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/0264-410x(94)90341-7","volume":"12","author":"G Sutter","year":"1994","unstructured":"Sutter G, Wyatt LS, Foley PL et al (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12(11):1032\u20131040. https:\/\/doi.org\/10.1016\/0264-410x(94)90341-7","journal-title":"Vaccine"},{"issue":"1","key":"20_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14760584.8.1.13","volume":"8","author":"JS Kennedy","year":"2009","unstructured":"Kennedy JS, Greenberg RN (2009) IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 8(1):13\u201324. https:\/\/doi.org\/10.1586\/14760584.8.1.13","journal-title":"Expert Rev Vaccines"},{"issue":"28","key":"20_CR8","doi-asserted-by":"publisher","first-page":"e2026207118","DOI":"10.1073\/pnas.2026207118","volume":"118","author":"A Tscherne","year":"2021","unstructured":"Tscherne A, Schwarz JH, Rohde C et al (2021) Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proc Natl Acad Sci USA 118(28):e2026207118. https:\/\/doi.org\/10.1073\/pnas.2026207118","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"20_CR9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/s1473-3099(20)30248-6","volume":"20","author":"T Koch","year":"2020","unstructured":"Koch T, Dahlke C, Fathi A et al (2020) Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis 20(7):827\u2013838. https:\/\/doi.org\/10.1016\/s1473-3099(20)30248-6","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"20_CR10","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1038\/s41467-022-31557-0","volume":"13","author":"A Fathi","year":"2022","unstructured":"Fathi A, Dahlke C, Kr\u00e4hling V et al (2022) Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. Nat Commun 13(1):4182. https:\/\/doi.org\/10.1038\/s41467-022-31557-0","journal-title":"Nat Commun"},{"issue":"24","key":"20_CR11","doi-asserted-by":"publisher","first-page":"e159895","DOI":"10.1172\/jci159895","volume":"132","author":"C Meyer zu Natrup","year":"2022","unstructured":"Meyer zu Natrup C, Tscherne A, Dahlke C et al (2022) Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. J Clin Invest 132(24):e159895. https:\/\/doi.org\/10.1172\/jci159895","journal-title":"J Clin Invest"},{"key":"20_CR12","unstructured":"Committee for Medicinal Product for Human Use (2010) Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-non-clinical-and-clinical-aspects-live-recombinant-viral-vectored-vaccines_en.pdf. Accessed 10 Aug 2010"},{"issue":"3","key":"20_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1128\/jvi.49.3.857-864.1984","volume":"49","author":"M Mackett","year":"1984","unstructured":"Mackett M, Smith GL, Moss B (1984) General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 49(3):857\u2013864. https:\/\/doi.org\/10.1128\/jvi.49.3.857-864.1984","journal-title":"J Virol"},{"issue":"2","key":"20_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nmeth734","volume":"2","author":"A Domi","year":"2005","unstructured":"Domi A, Moss B (2005) Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambda-based recombination. Nat Methods 2(2):95\u201397. https:\/\/doi.org\/10.1038\/nmeth734","journal-title":"Nat Methods"},{"issue":"1\u20132","key":"20_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jviromet.2010.04.012","volume":"168","author":"MG Cottingham","year":"2010","unstructured":"Cottingham MG, Gilbert SC (2010) Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. J Virol Methods 168(1\u20132):233\u2013236. https:\/\/doi.org\/10.1016\/j.jviromet.2010.04.012","journal-title":"J Virol Methods"},{"issue":"1","key":"20_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/v10010050","volume":"10","author":"A Okoli","year":"2018","unstructured":"Okoli A, Okeke MI, Tryland M et al (2018) CRISPR\/Cas9-advancing orthopoxvirus genome editing for vaccine and vector development. Viruses 10(1):50. https:\/\/doi.org\/10.3390\/v10010050","journal-title":"Viruses"},{"issue":"14","key":"20_CR17","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1128\/jvi.00687-09","volume":"83","author":"LS Wyatt","year":"2009","unstructured":"Wyatt LS, Earl PL, Xiao W et al (2009) Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 83(14):7176\u20137184. https:\/\/doi.org\/10.1128\/jvi.00687-09","journal-title":"J Virol"},{"key":"20_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1385\/1-59259-789-0:077","volume":"269","author":"C Staib","year":"2004","unstructured":"Staib C, Drexler I, Sutter G (2004) Construction and isolation of recombinant MVA. Methods Mol Biol 269:77\u2013100. https:\/\/doi.org\/10.1385\/1-59259-789-0:077","journal-title":"Methods Mol Biol"},{"issue":"6","key":"20_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2144\/00286st04","volume":"28","author":"C Staib","year":"2000","unstructured":"Staib C, Drexler I, Ohlmann M et al (2000) Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28(6):1137\u20131142, 1144\u20136, 1148. https:\/\/doi.org\/10.2144\/00286st04","journal-title":"Biotechniques"},{"issue":"25","key":"20_CR20","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1016\/j.vaccine.2007.04.002","volume":"25","author":"AF Antonis","year":"2007","unstructured":"Antonis AF, van der Most RG, Suezer Y et al (2007) Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 25(25):4818\u20134827. https:\/\/doi.org\/10.1016\/j.vaccine.2007.04.002","journal-title":"Vaccine"},{"issue":"4","key":"20_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/vaccines10040533","volume":"10","author":"A Kupke","year":"2022","unstructured":"Kupke A, Volz A, Dietzel E et al (2022) Protective CD8+ T cell response induced by modified vaccinia virus Ankara delivering Ebola virus nucleoprotein. Vaccines (Basel) 10(4):533. https:\/\/doi.org\/10.3390\/vaccines10040533","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"20_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/pathogens12070867","volume":"12","author":"MC Langenmayer","year":"2023","unstructured":"Langenmayer MC, Luelf-Averhoff AT, Marr L et al (2023) Newly designed poxviral promoters to improve immunogenicity and efficacy of MVA-NP candidate vaccines against lethal influenza virus infection in mice. Pathogens 12(7):867. https:\/\/doi.org\/10.3390\/pathogens12070867","journal-title":"Pathogens"},{"key":"20_CR23","doi-asserted-by":"publisher","first-page":"1182963","DOI":"10.3389\/fimmu.2023.1182963","volume":"14","author":"M Kubinski","year":"2023","unstructured":"Kubinski M, Beicht J, Zdora I et al (2023) A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection. Front Immunol 14:1182963. https:\/\/doi.org\/10.3389\/fimmu.2023.1182963","journal-title":"Front Immunol"},{"issue":"1","key":"20_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/vaccines12010105","volume":"12","author":"M Kubinski","year":"2024","unstructured":"Kubinski M, Beicht J, Gerlach T et al (2024) Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infection. Vaccines (Basel) 12(1):105. https:\/\/doi.org\/10.3390\/vaccines12010105","journal-title":"Vaccines (Basel)"},{"key":"20_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-1-61779-876-4_4","volume":"890","author":"M Kremer","year":"2012","unstructured":"Kremer M, Volz A, Kreijtz JH et al (2012) Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol Biol 890:59\u201392. https:\/\/doi.org\/10.1007\/978-1-61779-876-4_4","journal-title":"Methods Mol Biol"},{"key":"20_CR26","first-page":"145","volume":"24","author":"H Towbin","year":"1992","unstructured":"Towbin H, Staehelin T, Gordon J (1992) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 24:145\u2013149","journal-title":"Biotechnology"},{"issue":"7","key":"20_CR27","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1073\/pnas.76.7.3116","volume":"76","author":"J Renart","year":"1979","unstructured":"Renart J, Reiser J, Stark GR (1979) Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure. Proc Natl Acad Sci USA 76(7):3116\u20133120. https:\/\/doi.org\/10.1073\/pnas.76.7.3116","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"20_CR28","doi-asserted-by":"publisher","first-page":"6318","DOI":"10.1128\/jvi.00427-06","volume":"80","author":"DC Tscharke","year":"2006","unstructured":"Tscharke DC, Woo WP, Sakala IG et al (2006) Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB\/c mice. J Virol 80(13):6318\u20136323. https:\/\/doi.org\/10.1128\/jvi.00427-06","journal-title":"J Virol"},{"issue":"1","key":"20_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1084\/jem.20041912","volume":"201","author":"DC Tscharke","year":"2005","unstructured":"Tscharke DC, Karupiah G, Zhou J et al (2005) Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201(1):95\u2013104. https:\/\/doi.org\/10.1084\/jem.20041912","journal-title":"J Exp Med"}],"container-title":["Methods in Molecular Biology","Vaccinia, Mpox, and Other Poxviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4160-6_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T02:47:30Z","timestamp":1743130050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4160-6_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"ISBN":["9781071641590","9781071641606"],"references-count":29,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4160-6_20","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"3 December 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}